Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Has Consensus Target Price of $35.50 According to Brokerages

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has been given an average rating of “Hold” by the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $35.50.

LKFT has been the topic of several analyst reports. Morgan Stanley started coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, October 20th. They issued an “equal weight” rating and a $26.00 price objective on the stock. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. Royal Bank Of Canada upgraded Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. UBS Group raised Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd. Finally, TD Cowen started coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a “buy” rating for the company.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently added to or reduced their stakes in the company. ABC Arbitrage SA purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter worth approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth approximately $248,000. Finally, QRG Capital Management Inc. increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock valued at $591,000 after purchasing an additional 3,535 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.8%

Lakefront Biotherapeutics American Depositary Shares stock opened at $32.33 on Friday. The firm has a market cap of $2.13 billion, a PE ratio of -22.93 and a beta of 0.24. Lakefront Biotherapeutics American Depositary Shares has a 52-week low of $25.68 and a 52-week high of $36.24. The company’s 50 day moving average is $29.41 and its two-hundred day moving average is $29.98.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.97) by $1.00. The business had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $7.29 million. On average, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -1.26 earnings per share for the current fiscal year.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.